After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. (BioWorld Today)

Last week marked the end of approvable and not-approvable letters, as the FDA's Center for Drug Evaluation and Research adopted the Center for Biologics Evaluation and Research standard of issuing complete responses. (BioWorld Financial Watch)

As three of its own Immunodrug vaccine candidates advance through clinical trials, Cytos Biotechnology AG signed a CHF150 (US$139 million) technology deal with Pfizer Inc.'s vaccine unit. (BioWorld Today)